根据最新披露的股权安排，在完成相关交易后，Adial Pharmaceuticals的普通股持股比例已明确划分。原Adial股东将保留7.7%的股权，Azora方面将持有51%的股份，而其他投资方则共同拥有剩余41.3%的普通股份额。这一股权结构标志着公司资本层面的重大调整。
根据最新披露的股权安排，在完成相关交易后，Adial Pharmaceuticals的普通股持股比例已明确划分。原Adial股东将保留7.7%的股权，Azora方面将持有51%的股份，而其他投资方则共同拥有剩余41.3%的普通股份额。这一股权结构标志着公司资本层面的重大调整。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.